Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

22
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
22
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

Cancers·2026
Same author

Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study.

Journal of clinical medicine·2026
Same author

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer.

Journal of ovarian research·2026
Same author

Nailfold capillaroscopy findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction.

BMC cancer·2026
Same author

A Machine Learning Framework for Prognostic Modeling in Stage III Colon Cancer.

Journal of clinical medicine·2026

相关实验视频

Updated: Jul 14, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K

卡博赞提尼布诱导的心力衰竭

Serhat Sekmek1, Dogan Bayram1, Gokhan Ucar1

  • 1Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
|October 11, 2023
PubMed
概括

卡博桑提尼布是一种癌症药物,很少会导致永久性心力衰竭. 这一案例凸显了甲状腺癌患者治疗前后心脏监测的重要性.

科学领域:

  • 在瘤学瘤学.
  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 卡博桑提尼布是一种多酶抑制剂,用于治疗各种癌症.
  • 心力衰竭是卡博赞提尼布极为罕见的副作用,仅有有限的已发表病例.
  • 这份报告详细介绍了卡博赞提尼布诱导的心力衰竭病例,该病例发生在患有耐火性甲状腺癌的患者身上.

研究的目的:

  • 报告一个罕见的卡博赞提尼布引起的心力衰竭病例.
  • 为了强调卡博赞提尼布治疗可能导致严重心脏后果的可能性.
  • 为了强调接受卡博赞提尼布治疗的患者心脏监测的重要性.

主要方法:

  • 一名没有心血管病史的57岁妇女接受了甲状腺癌治疗的卡博赞提尼布.
  • 治疗前的心声图显示心脏功能正常.
  • 在卡博赞提尼布治疗2个月后,观察到心脏功能下降 (排泄分数30%,全球低动能症).

主要成果:

  • 患者出现了心力衰竭的症状,包括胀和呼吸短促.
  • 停止卡博赞提尼布治疗并没有恢复心脏功能.
  • 在这种情况下,心力衰竭被认为是永久性的.
关键词:
卡博桑提尼布 (Cabozantinib) 是一种药物.心脏衰竭是因为心脏衰竭.甲状腺癌是一种癌症.

更多相关视频

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

相关实验视频

Last Updated: Jul 14, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

结论:

  • 卡博赞提尼布诱导的心力衰竭是一种罕见但严重的不良事件.
  • 虽然这种情况可能是可逆的,但它表明永久性心脏损伤是可能的.
  • 在卡博赞提尼布治疗前后定期进行心脏病评估对于早期检测和管理至关重要.